Cancer cell lipid membrane

Cancer cell lipid membranes are characterized by significant alterations in lipid composition and organization compared to their healthy counterparts, making them a viable target for selective cancer therapy. A hallmark of these membranes is the loss of phospholipid asymmetry, resulting in the externalization of phosphatidylserine and phosphatidylethanolamine, which imparts a net negative charge to the cell surface (Birge et al., 2016). This negative charge, combined with increased membrane fluidity and altered cholesterol content, allows for the selective recruitment of cationic host defense peptides and synthetic alkylphospholipids (Hoskin and Ramamoorthy, 2008). Once associated with the membrane, these agents can induce cell death through direct physical disruption, such as pore formation and lysis, or by interfering with membrane-resident signaling hubs known as lipid rafts (Mollinedo et al., 2004). Because these therapies target the fundamental structural integrity of the cancer cell, they are less susceptible to common resistance mechanisms like efflux pump upregulation or target protein mutations. Consequently, the cancer cell lipid membrane serves as a critical interface for developing broad-spectrum, membrane-active oncology therapeutics that exploit biophysical differences between malignant and normal cells.

Other names

Tumor cell membraneCancer cell plasma membraneNeoplastic cell membraneMalignant cell membrane

Induction of membrane permeabilization and pore formation; modulation of lipid raft-associated signaling pathways (e.g., PI3K/Akt); and targeting of externalized phosphatidylserine to trigger antibody-dependent cellular cytotoxicity or apoptosis.